Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SREBF2 | Q12772 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 6/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10041932 | 0.95 | SREBF2 (0.43) | SREBF2CYP17A1CNR2HDAC3HDAC1 | |
| SCHEMBL407639 | 0.81 | CTSK (0.37) | SREBF2CYP17A1CNR2HDAC3HDAC1 | |
| SCHEMBL403105 | 0.80 | CYP17A1 (0.42) | SREBF2CYP17A1CNR2HDAC3HDAC1 | |
| SCHEMBL10071168 | 0.80 | CYP17A1 (0.39) | SREBF2CYP17A1CNR2HDAC3HDAC1 | |
| SCHEMBL19265408 | 0.76 | CA12 (0.47) | SREBF2CYP17A1HDAC3HDAC1HDAC2 | |
| SCHEMBL402987 | 0.75 | TLR8 (0.40) | CNR2 | |
| SCHEMBL21049585 | 0.73 | SPHK1 (0.59) | CYP17A1 | |
| SCHEMBL15139200 | 0.73 | CYP17A1 (0.52) | CYP17A1DRD2MAP4K4BRD4CREBBP | |
| SCHEMBL13181089 | 0.72 | HPGD (0.57) | CYP17A1DRD2 | |
| SCHEMBL10041933 | 0.69 | TLR8 (0.43) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9293739-B2 | Process and materials for making contained layers and devices made with same | E I DU PONT DE NEMOURS AND COMPANY (US) | 2016-03-22 | — | — | US | disclosed |
| US-20140349431-A1 | PROCESS AND MATERIALS FOR MAKING CONTAINED LAYERS AND DEVICES MADE WITH SAME | EI DU PONT DE NEMOURS AND COMPANY (US) | 2014-11-27 | — | — | US | disclosed |
| US-20120065432-A1 | ELECTROACTIVE MATERIALS | E.I DU PONT DE NEMOURS AND COMPANY (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065432-A1 | ELECTROACTIVE MATERIALS | NAT1, ADRA1D, ADRA1B | SREBF2 1734/4885CYP17A1 143/4885CNR2 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.